Page 27 - Read Online

Kaehler et al. Cancer Drug Resist 2019;2:18-30 I http://dx.doi.org/10.20517/cdr.2019.05 Page 27

RefeReNCes
1. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 2015;526:343-50.
2. Filipski KK, Mechanic LE, Long R, Freedman AN. Pharmacogenomics in oncology care. Front Genet 2014;5:73.
3. Gillis NK, Patel JN, Innocenti F. Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation
sequencing era. Clin Pharmacol Ther 2014;95:269-80.
4. Oscarson M. Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine. Clin Chem Lab Med
2003;41:573-80.
5. Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, et al. Clinical pharmacogenetics implementation consortium guidelines for
dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 2013;94:640-5.
6. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, et al. 11 years’ follow-up of trastuzumab after adjuvant
chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet 2017;389:1195-205.
7. O’Dwyer ME, Druker BJ. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
Lancet Oncol 2000;1:207-11.
8. Carr DF, Pirmohamed M. Biomarkers of adverse drug reactions. Exp Biol Med (Maywood) 2018;243:291-9.
9. Abaji R, Krajinovic M. Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease
and autoimmune disorders: influence on treatment response. Pharmgenomics Pers Med 2017;10:143-56.
10. Lee SHR, Yang JJ. Pharmacogenomics in acute lymphoblastic leukemia. Best Pract Res Clin Haematol 2017;30:229-36.
11. Paugh SW, Stocco G, McCorkle JR, Diouf B, Crews KR, et al. Cancer pharmacogenomics. Clin Pharmacol Ther 2011;90:461-6.
12. Schwab M, Schaffeler E, Marx C, Fischer C, Lang T, et al. Azathioprine therapy and adverse drug reactions in patients with
inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002;12:429-36.
13. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, et al. Clinical Pharmacogenetics Implementation Consortium
guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011;89:387-91.
14. Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, et al. Comprehensive analysis of thiopurine S-methyltransferase
phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants.
Pharmacogenetics 2004;14:407-17.
15. Wellmann R, Borden BA, Danahey K, Nanda R, Polite BN, et al. Analyzing the clinical actionability of germline pharmacogenomic
findings in oncology. Cancer 2018;124:3052-65.
16. Kim JH, Cheon JH, Hong SS, Eun CS, Byeon JS, et al. Influences of thiopurine methyltransferase genotype and activity on
thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study. J Clin Gastroenterol
2010;44:e242-8.
17. Jung YS, Cheon JH, Park JJ, Moon CM, Kim ES, et al. Correlation of genotypes for thiopurine methyltransferase and inosine
triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment
with thiopurine drugs. J Hum Genet 2010;55:121-3.
18. Yang SK, Hong M, Baek J, Choi H, Zhao W, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced
leukopenia. Nat Genet 2014;46:1017-20.
19. Moriyama T, Nishii R, Lin TN, Kihira K, Toyoda H, et al. The effects of inherited NUDT15 polymorphisms on thiopurine active
metabolites in Japanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics 2017;27:236-9.
20. Moriyama T, Yang YL, Nishii R, Ariffin H, Liu C, et al. Novel variants in NUDT15 and thiopurine intolerance in children with acute
lymphoblastic leukemia from diverse ancestry. Blood 2017;130:1209-12.
21. Yang JJ, Landier W, Yang W, Liu C, Hageman L, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine
intolerance in children with acute lymphoblastic leukemia. J Clin Oncol 2015;33:1235-42.
22. Yang JJ, Whirl-Carrillo M, Scott SA, Turner AJ, Schwab M, et al. Pharmacogene variation consortium gene introduction: NUDT15.
Clin Pharmacol Ther 2018; doi: 10.1002/cpt.1268.
23. Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, et al. Clinical pharmacogenetics implementation consortium (CPIC)
guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther 2018; doi: 10.1002/
cpt.1304.
24. Bosma P, Chowdhury JR, Jansen PH. Genetic inheritance of Gilbert’s syndrome. Lancet 1995;346:314-5.
25. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, et al. The genetic basis of the reduced expression of bilirubin UDP-
glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med 1995;333:1171-5.
26. Dean L. Irinotecan therapy and UGT1A1 genotype. Medical Genetics Summaries. MD, USA: Bethesda; 2012.
27. Barbarino JM, Haidar CE, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for UGT1A1.
Pharmacogenet Genomics 2014;24:177-83.
28. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J
Natl Cancer Inst 2007;99:1290-5.
29. Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, et al. UGT1A1 genotype and irinotecan therapy: general review and
implementation in routine practice. Fundam Clin Pharmacol 2015;29:219-37.
30. Fujii H, Yamada Y, Watanabe D, Matsuhashi N, Takahashi T, et al. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in
patients with colorectal cancer. Cancer Chemother Pharmacol 2019;83:123-9.
31. Tejpar S, Yan P, Piessevaux H, Dietrich D, Brauchli P, et al. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/
irinotecan toxicity: results of the PETACC-3 trial. Eur J Cancer 2018;99:66-77.